Tela Bio Inc

NASDAQ TELA

Data sourced from

and

Daily

Download Data

Tela Bio Inc Market Capitalization on June 03, 2024: USD 135.60 M

Tela Bio Inc Market Capitalization is USD 135.60 M on June 03, 2024, a -46.23% change year over year. Market capitalization is a financial metric that represents the total value of a publicly traded company. It is calculated by multiplying the current share price of a company by the total number of outstanding shares. Market capitalization is used to assess the size and relative value of a company in the stock market. It provides investors with an idea of the company's overall worth and is often used as a basis for comparing companies within the same industry or sector. A higher market capitalization generally indicates a larger, more established company.

Tela Bio Inc 52-week high Market Capitalization is USD 261.54 M on July 21, 2023, which is 92.87% above the current Market Capitalization.
Tela Bio Inc 52-week low Market Capitalization is USD 108.23 M on April 25, 2024, which is -20.19% below the current Market Capitalization.
Tela Bio Inc average Market Capitalization for the last 52 weeks is USD 173.74 M.

NASDAQ: TELA

Tela Bio Inc

CEO	Mr. Antony Koblish
IPO Date	Nov. 8, 2019
Location	United States
Headquarters	1 Great Valley Parkway, Malvern, PA, United States, 19355
Employees	227
Sector	Healthcare
Industry	Medical devices

Description

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key trends